Liquidia (NASDAQ:LQDA) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Liquidia (NASDAQ:LQDA) in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a $29.00 target price on the stock.

Several other brokerages also recently weighed in on LQDA. Wells Fargo & Company began coverage on shares of Liquidia in a research note on Friday, December 20th. They issued an “overweight” rating and a $20.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $19.00 target price on shares of Liquidia in a research note on Thursday, January 9th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Liquidia currently has an average rating of “Buy” and a consensus price target of $26.63.

Liquidia Price Performance

Shares of NASDAQ LQDA opened at $15.44 on Thursday. The firm has a fifty day moving average price of $14.73 and a 200-day moving average price of $12.14. Liquidia has a 1 year low of $8.26 and a 1 year high of $16.99. The stock has a market cap of $1.31 billion, a PE ratio of -9.47 and a beta of 0.07.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The company had revenue of $2.92 million for the quarter, compared to the consensus estimate of $4.60 million. On average, research analysts expect that Liquidia will post -1.51 EPS for the current year.

Insider Buying and Selling at Liquidia

In other news, CFO Michael Kaseta sold 23,370 shares of the firm’s stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $275,298.60. Following the sale, the chief financial officer now directly owns 401,755 shares in the company, valued at approximately $4,732,673.90. This trade represents a 5.50 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Rajeev Saggar sold 2,445 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $13.00, for a total transaction of $31,785.00. Following the completion of the sale, the insider now owns 267,943 shares in the company, valued at $3,483,259. This represents a 0.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 71,245 shares of company stock valued at $843,326. Company insiders own 30.10% of the company’s stock.

Institutional Trading of Liquidia

Institutional investors have recently modified their holdings of the company. Steward Partners Investment Advisory LLC bought a new stake in shares of Liquidia in the 4th quarter valued at about $59,000. Summit Investment Advisors Inc. boosted its holdings in shares of Liquidia by 35.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock valued at $78,000 after buying an additional 1,719 shares in the last quarter. D. E. Shaw & Co. Inc. bought a new stake in shares of Liquidia in the 4th quarter valued at about $142,000. EntryPoint Capital LLC bought a new stake in shares of Liquidia in the 4th quarter valued at about $154,000. Finally, Walleye Trading LLC boosted its stake in Liquidia by 54.7% in the 3rd quarter. Walleye Trading LLC now owns 13,201 shares of the company’s stock worth $132,000 after purchasing an additional 4,670 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).